CardioMech
Trondheim, NO · Incorporated in Norway · 1 known investors
CardioMech develops a transcatheter mitral valve repair system (MVRS) that delivers artificial chords via a transfemoral, transseptal catheter approach to treat degenerative mitral regurgitation on a beating heart. The device targets heart disease patients as a less-invasive alternative to open-heart surgery and is currently for investigational use only.
Founders & leadership
RN
Richard NehmNamed on SEC filing
JH
Jan HabrekkeNamed on SEC filing
VJ
Vic, Jr. BertrandNamed on SEC filing
JB
Jacob BergslandNamed on SEC filing
NH
Nikolai HiorthNamed on SEC filing
MN
Mark NovotnyNamed on SEC filing
Board
FE
Investors · 1
Reported raises · per SEC filings
Form D private placements$57.7M disclosed across 7 rounds · 2019–2025
▶$17.6MraisedApr 2025 · 58 investors · BiotechnologyRule 506(b)
▶$17.6MraisedApr 2025 · 58 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard NehmExecutive Officer, Director
- Florian EckhardtDirector
- Jan HabrekkeDirector
- Vic, Jr. BertrandDirector
- Offering amount
- $17.6M
- Amount sold
- $17.6M
- Minimum investment
- $10K
- First sale
- Apr 2025
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
▶$12.7MraisedDec 2023 · 100 investors · BiotechnologyRule 506(b)
▶$12.7MraisedDec 2023 · 100 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard NehmExecutive Officer, Director
- Jacob BergslandDirector
- Vic, Jr. BertrandDirector
- Offering amount
- $12.7M
- Amount sold
- $12.7M
- Minimum investment
- $5K
- First sale
- Dec 2023
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
▶$4.5MraisedFeb 2023 · 38 investors · BiotechnologyRule 506(b)
▶$4.5MraisedFeb 2023 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vic Bertrand, Jr.Director
- Florian EckhardtDirector
- Mark NovotnyDirector
- Richard NehmExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Minimum investment
- $10K
- First sale
- Feb 2023
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
▶$6.2MraisedApr 2022 · 34 investors · BiotechnologyRule 506(b)
▶$6.2MraisedApr 2022 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vic, Jr. BertrandDirector
- Florian EckhardtDirector
- Mark NovotnyDirector
- Richard NehmExecutive Officer, Director
- Offering amount
- $6.2M
- Amount sold
- $6.2M
- Minimum investment
- $5K
- First sale
- Apr 2022
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
▶$9.2MraisedAug 2020 · 4 investors · BiotechnologyRule 506(b)
▶$9.2MraisedAug 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark NovotnyDirector
- Richard NehmExecutive Officer, Director
- Vic, Jr. BertrandDirector
- Florian EckhardtDirector
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- Minimum investment
- $733.3K
- First sale
- Aug 2020
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
▶$5MraisedAug 2019 · 54 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2019 · 54 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard NehmExecutive Officer, Director
- Jacob BergslandExecutive Officer, Director
- Frederik Justin Gabriel GroenewegenDirector
- Vic Joseph BertrandDirector
- Nikolai HiorthExecutive Officer
- Mark NovotnyDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $10K
- Proceeds to insiders
- $400K
- First sale
- Aug 2019
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
▶$2.5MraisedFeb 2019 · 39 investors · BiotechnologyRule 506(b)
▶$2.5MraisedFeb 2019 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob BergslandExecutive Officer, Director
- Richard NehmExecutive Officer, Director
- Nikolai HiorthExecutive Officer
- Mark NovotnyDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Minimum investment
- $15K
- Proceeds to insiders
- $170K
- First sale
- Feb 2019
- Incorporated
- Other, Norway
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Rf Surgical6 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Cardiovalve5 shared keywordsCardiovalve develops a transcatheter valve replacement system designed to fit both mitral and tricuspid anatomies via transfemoral delivery, avoiding open heart surgery. The device targets structural heart disease and is currently restricted to research use.
Corcym4 shared keywordsCorcym is a medical device company that develops therapies and devices for patient care. The page emphasizes product safety information and customer support for medical device users.
4C Medical Technologies4 shared keywords4C Medical develops minimally invasive medical devices for structural heart disease, including mitral and tricuspid valve treatments. The company serves interventional cardiologists and patients requiring catheter-based cardiac interventions.
Merit Medical4 shared keywordsMerit Medical Systems designs, develops, manufactures and markets medical devices for interventional and diagnostic procedures. The company serves healthcare providers and clinical practitioners in the medical device industry.
Topera3 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Micro Interventional Devices3 shared keywordsMicro Interventional Devices designs and manufactures medical devices for transcatheter cardiac repair procedures, enabling minimally invasive alternatives to open-heart surgery. The company initially focuses on transcatheter mitral and tricuspid valve repair solutions.
Companies competing with CardioMech for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CardioMech do?
- CardioMech develops a transcatheter mitral valve repair system (MVRS) that delivers artificial chords via a transfemoral, transseptal catheter approach to treat degenerative mitral regurgitation on a beating heart. The device targets heart disease patients as a less-invasive alternative to open-heart surgery and is currently for investigational use only.
- Who are CardioMech's investors?
- CardioMech's investors include Hadean Ventures.
- How much funding has CardioMech raised?
- CardioMech has disclosed $57.7M raised across 7 rounds.
- Where is CardioMech headquartered?
- CardioMech is headquartered in Trondheim, NO.